Base Year
Historical Year
Forecast Year
The growth of the global Cyclophosphamide drug market is expected to grow with a CAGR of 2.2% during the forecast period of 2024-2032, driven by the growing incidences of cancer. The market is expected to reach a value of USD 827.91 million by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
These drugs are classified as alkylating agents. It slows or stops the growth of cancer cells in the body when used in the treatment of cancer. It suppresses the body's immune system when used to treat nephrotic syndrome. A kidney condition, known as nephrotic syndrome, makes the body excrete excessive amounts of protein in urine. The clusters of tiny blood capillaries in the kidneys that filter waste and extra water from the blood are typically damaged by nephrotic syndrome.
Cyclophosphamide, solely or in combination with other drugs, is used for the treatment of various cancers, like lymphoma, myeloma, and leukaemia. It is also used in the therapy of retinoblastoma, neuroblastoma, ovarian cancer, and breast cancer. Metabolites is the main way through which the drug is excreted from the body.
Neutropenia, febrile neutropenia, fever, alopecia, nausea, vomiting, and diarrhoea are the adverse effects that are most frequently reported.
According to the Cyclophosphamide drug market research report, the market can be categorised into the following segments:
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Breakup by Route of Administration
Market by Dose
Market by Disease
Market by Distribution Channel
Market Breakup by Region
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The Cyclophosphamide drug is on the list of essential medicines by WHO. The demand for the drug is increasing with increased cases of cancer among the population in the future. More combinations are under development and trial for the treatment of wide spectrum of diseases.
It is used as an alkylating drug to stop and slow the growth of tumours by directly damaging DNA and cross-linking guanine bases in DNA double-helix strands. It is used to treat several cancers, including lung cancer, breast cancer, eye cancer, blood cell cancer, white bone, and bone marrow cancer. This drug is used to treat a particular form of kidney illness in children with nephrotic syndrome. Product consumption will increase as healthcare industry grows. Therefore, throughout the anticipated period, the growth of the market would be driven by the rising demand.
The Cyclophosphamide drug market in Asia Pacific is expected to increase gradually. The rapid rise in the healthcare industry can be attributed to the increase. Furthermore, an increasing number of disorders, such as blood cell cancer and lung cancer, have increased the product in the nephrotic syndrome and AL amyloidosis, which will drive market expansion in North America. Increased use of Cyclophosphamide drugs in hospitals and clinics is driving the growth in Europe.
The report gives an in-depth analysis of the key players involved in the global Cyclophosphamide drug market, sponsors manufacturing the therapies, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Route of Administration |
|
| Breakup by Dose |
|
| Breakup by Disease |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us today for customized, data-driven solutions tailored to your unique requirements!
The market value was about USD 680.65 million in 2023, driven by the rising cases of cancer.
The market is likely to grow at a CAGR of 2.2% during the forecast period of 2024-2032 to attain a value of USD 827.91 million by 2032.
Cancers of the ovaries, breast, blood and lymphatic systems, and nerves are all treated with Cyclophosphamide drug (mainly in children). Retinoblastoma, a bone marrow malignancy that primarily affects youngsters, multiple myeloma, and mycosis fungoides, are all treated with Cyclophosphamide drug (tumours on the skin).
The major regions in the global market are North America, Latin America, Asia Pacific, Europe, and Middle East and Africa.
The drug causes various side effects including nausea, vomiting, and appetite loss.
It does not work immediately and usually takes about 6 weeks to start working.
The average percentage of objective responses is 43%. This includes a 38% response rate for individuals who have already received treatment and a 29% response rate for patients who had previously failed to respond to the drug.
In some ANCA-associated vasculitis (AAV) patients, mycophenolate mofetil (MMF) may be a safe and effective substitute for the drug.
The key players in this market include Baxter Laboratories Ltd., Novartis AG, Himka Pharmaceuticals Plc., Amneal Pharmaceuticals LLC, NorthStar Rx LLC, Aurobindo Pharma Ltd., CSC Pharmaceutical International, Jiangsu Hengrui Medicine Co Ltd, Nodus Oncology, Abbive, Inc., Theravance Biopharm, Inc., Sanofi S.A., Roxane Laboratories Pvt Ltd, and LGM Pharma Llc, among others.
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Pricing Plans
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Subscribe to our Newsletter
By subscribing you agree to with our privacy policy and provide
consent to
receive
updates
from our company.
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61 448 06 17 27
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-120-433-0800
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63 287899028, +63 967 048 3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84865399124
